News & Updates

Large data from a federated meta-analysis point to high amounts of red and processed meat and poultry consumption as a risk factor for type 2 diabetes (T2D) in populations globally.

For the past three decades, intakes of sugar-sweetened beverages (SSBs) among children and adolescents across 185 countries have increased by nearly a quarter, reports a study. This increase matches the rise in obesity prevalence among young people worldwide.

Diabetic kidney disease (DKD) is a global healthcare burden. At a symposium co-organized by Diabetes Hongkong and Hong Kong Society of Nephrology, Professor Ronald Ma of the Chinese University of Hong Kong discussed the current landscape of DKD in Hong Kong, and Dr Masayuki Yamanouchi, a specialist in nephrology from Toranomon Hospital in Tokyo, Japan, discussed clinical and real-world evidence on the effects of a nonsteroidal mineralocorticoid receptor antagonist (MRA), finerenone, in improving outcomes in patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD). Dr Yamanouchi also presented two patient cases to illustrate the clinical benefits of finerenone in DKD patients with different disease severity.

Obesity does not appear to elevate the risk of death in critically ill patients with COVID-19, results of a study have shown. In addition, patients with BMI <25 kg/m2 have a higher rate of mortality than those with greater BMI levels.

Individuals with type 2 diabetes (T2D) treated in routine clinical care appear to fare better with glucagon-like peptide-1 receptor agonists (GLP-1RAs) than with dipeptidyl peptidase-4 inhibitors (DPP-4is), with GLP-1Ras being associated with lower rates of hyperkalemia and renin-angiotensin system inhibitor (RASi) medication discontinuation, as shown in an observational study.

The incidence of cirrhosis and hepatocellular carcinoma (HCC) among veterans differs according to demographic and clinical characteristics, with the lowest rate seen among Asians, reports a study.

Combination therapy with sodium-glucose transporter inhibitors (SGLT2i) and glucagon-like peptide receptor agonists (GLP1ra) prevents heart failure and improves long-term survival in a real-world population as compared with SGLT2i or GLP1ra monotherapy, according to a study.